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The interaction between a cationic polyelectrolyte, chitosan, and an exogenous bovine lung extract surfactant (BLES) was studied using dynamic
compression/expansion cycles of dilute BLES preparations in a Constrained Sessile Drop (CSD) device equipped with an environmental chamber
conditioned at 37 °C and 100% R.H. air. Under these conditions, dilute BLES preparations tend to produce variable and relatively high minimum
surface tensions. Upon addition of “low” chitosan to BLES ratios, the minimum surface tension of BLES–chitosan preparations were consistently
low (i.e. b5 mJ/m2), and the resulting surfactant monolayers (adsorbed at the air–water interface) were highly elastic and stable. However, the use of
“high” chitosan to BLES ratios induced the collapse of the surfactant monolayer at high minimum surface tensions (i.e. N15 mJ/m2). The zeta
potential of the lung surfactant aggregates in the subphase suggests that chitosan binds to the anionic lipids (phosphatidyl glycerols) in BLES, and that
this binding is ultimately responsible for the changes in the surface activity (elasticity and stability) of these surfactant–polyelectrolyte mixtures.
Furthermore the transition from “low” to “high” chitosan to BLES ratios correlates with the flocculation and de-flocculation of surfactant aggregates
in the subphase. It is proposed that the aggregation/segregation of “patches” of anionic lipids in the surfactant monolayer produced at different
chitosan to BLES ratios explains the enhancing/inhibitory effects of chitosan. These observations highlight the importance of electrostatic
interactions in lung surfactant systems.
© 2007 Elsevier B.V. All rights reserved.Keywords: Polyelectrolyte; Surface tension; Zeta potential; Respiratory distress syndrome1. Introduction
Respiratory distress syndrome (RDS) is a condition that affects
preterm neonates (nRDS) with premature lungs that are not yet
capable of producing lung surfactants, and adults (ARDS) whose
lungs are afflicted by a serious injury that typically produces
inactive lung surfactant films [1,2]. The introduction of surfactant
replacement therapy in the 1980s has reduced the mortality of
nRDS patients to less than half [1–3]. Unfortunately, lung
surfactant therapy has been ineffective in reducing themortality of
ARDS patients or nRDS patients where the alveolar fluid is⁎ Corresponding author. Department of Chemical Engineering and Applied
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doi:10.1016/j.bbamem.2007.10.003severely compromised by inhibitory factors such as serum
proteins [1,2,4–6].
Lung surfactants were first defined by Pattle as a complex
mixture of phospholipids and proteins [7,8]. After calculating the
Laplace pressure in alveoli of different sizes, Pattle concluded that
the surface tension (γ) of the alveoli should be close to zero in
order to avoid alveoli collapse. In general, it is necessary to ensure
that surface tensions of 5 mJ/m2 or less are attained at the end of
the expiration to prevent lung collapse [1,4,5,9].
Lung surfactants are produced and recycled by Type II pneu-
mocytes. On average, lung surfactants are composed of 70–80%
phosphatidylcholines (PC), 10–15% phosphatidylglycerols
(PG), 7–10% proteins, 4–7% neutral lipids (mostly cholesterol),
and minor fractions of other phospholipids [10–12]. Dipalmi-
toylphosphatidylcholine (DPPC) is the main PC species (50% of
total surfactant) in lung surfactants, and has a net zero charge.
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species and is negatively charged at physiological conditions.
DPPC is considered to be the molecule responsible for pro-
ducing near zero surface tension upon compression [1]. How-
ever, DPPC requires the presence of surfactant proteins and ionic
lipids to facilitate the exchange of material with the subphase
[13,14]. Neutral lipids (in particular cholesterol) have been
found to influence the lateral phase separation of lung surfactant
films, and the spreading properties of lung surfactant aggregates
[15]. There are four lung surfactant proteins: SP-A, SP-B, SP-C,
and SP-D [16]. SP-A is the most abundant of the proteins and is
hydrophilic and negatively charged. SP-B is a hydrophobic and
positively charged protein which is considered essential to lung
surfactants since SP-B deficiency is a lethal condition [17].
Various exogenous surfactant formulations have been pro-
duced for surfactant replacement therapy [1]. Bovine Lipid
Extract Surfactant (BLES) is one of these. BLES is obtained
using a solvent extraction process that removes water soluble
components such as SP-A and SP-D. BLES has shown to be an
effective surfactant in the treatment of neonatal respiratory
distress syndrome (nRDS), and is one of the exogenous lung
surfactant replacement preparation approved in Canada [18,19].
BLES contains nearly 40–45% DPPC, ∼35% unsaturated PCs,
10–12% PGs, ∼2% phosphatidylinositol (PI), ∼3% phospha-
tidylethanolamine (PE), ∼1.5% lyso-bis-phosphatidic acid
(lyso-bis-PA), and ∼2.5% sphingomyelin (SM), 1–2% proteins
SP-B and SP-C. The neutral lipids (including cholesterol) are
removed after washing the extracted material with acetone
[18,20–22]. The range in composition indicated above for key
components like SP-B and SP-C proteins, DPPC and PGs is to
be expected from natural sources like bovine lungs, and can be
expected to lead to batch to batch variations.
Numerous additives are currently under consideration to
improve the effectiveness of exogenous lung surfactant for-
mulations. A number of these additives are surface active pro-
tein analogs (in particular the cationic protein SP-B) [23,24],
and cationic antibiotics such as polymyxin B [25,26]. Nonionic
polymers such as dextran or polyethylene glycol (PEG) have
also been considered [20,27–34]. However, these nonionic
polymers need to be formulated at relatively high concentra-
tions, and this leads to viscous solutions that are difficult to
instill and have sometimes been found detrimental to the for-
mulation [35]. The mechanism of action of these nonionic
polymeric additives is based on a depletion–attraction effect
[28,36] as ionic moieties are not present in the polymers. The
depletion attraction mechanism proposes that, at high polymer
concentrations, the difference in osmotic pressure between the
polymer solution and the liquid in between the lipid vesicles is
high enough to induce the “fusion” of the vesicles into larger
aggregates. It is believed that these larger aggregates produce a
rapid exchange of material with the surfactant film adsorbed at
the air/water interface, leading to films enriched in DPPC that
yield lower surface tensions.
Hyaluronan, an anionic polymer, has also been used to
produce the same effects using lower polymer concentration
[37,38]. While hyaluronan has produced a substantial improve-
ment in terms of achieving inhibition reversal with low polymerconcentrations (thus reducing the viscosity of the formulation),
it is less effective than chitosan at improving the surface activity
(fast adsorption, high dilatational elasticity) and reversing
BLES inhibition [39].
A previous study has found that the chitosan concentration
needed to reverse BLES inhibition is 500 times lower than that
required by PEG to achieve the same effect [39]. Given the low
concentrations at which chitosan is effective, and the fact that
chitosan itself is not surface active (equilibrium surface tension
of chitosan alone is 67.4±0.3 mJ/m2 — see Ref. [39]), it was
proposed that the electrostatic interactions between anionic
lipids and chitosan might be responsible for the observed
phenomena [39]. However, a corroboration and understanding
of this electrostatic interaction hypothesis between chitosan and
BLES was yet to be pursued. In previous work [39] only a
limited range of chitosan concentrations (no higher than 0.1 mg/
ml) was considered and the optimal chitosan dosage was not
systematically studied. The main objective of this work is to
investigate the interaction between BLES and chitosan and to
determine the optimal chitosan dosage for different surfactant
concentrations. To this end, the surface tension of several chi-
tosan–BLES formulations have been evaluated using dynamic
compression/expansion cycles that mimic physiological condi-
tions. The relation between BLES concentration and optimal
chitosan dosage (defined as the concentration of chitosan that
produces lowest minimum surface tension upon compression) is
explored via optical micrographs and zeta potential measure-
ments of the subphase surfactant aggregates.
2. Materials and methods
2.1. Materials
Bovine Lipid Extract Surfactant (BLES) was provided by BLES
Biochemicals Inc. (London, ON, Canada) and used without further purification
[20,27,28,40]. BLES was stored at −20 °C with an initial concentration of 27 mg
lipids/ml and distributed into 1 ml glass vials in a N2 atmosphere. On the day of
experiment, one vial was first incubated in a 37.5 °C water bath for 1 h, before
dissolving in a salt solution of 0.6% NaCl and 1.5 mM CaCl2 [39]. BLES
preparations containing 0.5, and 2.0 mg lipids/ml solution were prepared. These
BLES preparations had a pH value of 5–6.
Chitosan (Cat. No. 448869, Mr 612 kDa, degree of deacetylation 75–85%)
was purchased from Sigma-Aldrich. Further characterization for this chitosan
can be found elsewhere [41]. 100 mg Chitosan was first dissolved in 9 ml
0.05 M hydrochloric acid overnight to ensure complete dissolution. The
prescribed amount of chitosan (according to the specific formulation) was
withdrawn and added to the NaCl/CaCl2 salt solution on the day of the expe-
riment [39]. For each experiment, the chitosan solution was added to an equal
volume of the BLES suspension. The final pH of these chitosan–BLES
suspensions ranged from 5 to 5.5. The chitosan concentration in lung surfactant
preparations ranged from 0.01 to 0.5 mg/ml.
2.2. Methods
2.2.1. Surface tension measurements
After gentle vortexing, the BLES–chitosan mixture was loaded into a motor-
driven syringe (2.5 ml, #1002, Gastight), ready for dynamic surface tension
measurements using the Constrained Sessile Drop (CSD) surfactometer. The
CSD apparatus allows measurements of low surface tension in lung surfactant
systems regardless of the surfactant concentration [40,42]. The details of the
design and operation of the CSD device has been described elsewhere
[40,42,43]. The operation of the CSD device begins when a sessile drop of the
Fig. 1. Surface tension and surface area output for film formation and dynamic cycling experiments. BLES 0.5 mg/ml compressed at 3 s/cycle periodicity in humid
(100% R.H.) air. Stages 1 through 4 correspond to film compression, film relaxation, film expansion and film re-absorption respectively.
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(3 mm diameter). The pedestal has a sharp-knife edge (60° angle of approach) to
prevent the spreading of the test liquid when the lipid film reaches a near zero
surface tension at the end of the compression stage. During the experiments, the
droplet and the pedestal are enclosed in a chamber that allows the control of gas
composition and temperature. The humidity in the chamber was kept constant at
100% relative humidity at 37 °C. A CCD camera (Model 4815-5000, Cohu
Corp., Poway, CA) was used to acquire the images of the drop throughout the
experiment at a rate of 15 images/s. The acquired images were processed by a
digital video processor (Snapper-8, Acsire Silicon Ltd., Uxbridge, UK) and
stored in a workstation (Sun Blade 1500, Sun Microsystems Inc., Santa Clara,
CA) for further analysis by Axisymmetric Drop Shape Analysis (ADSA) [43].Table 1
Surface tension at equilibrium (S.T.eq), minimum surface tension (S.T.min), and
dilatational elasticity (ɛ) of dilute (0.5 mg/ml) BLES preparations (at 10% area
reduction) compressed with a periodicity of 3 s/cycle and 20% area reduction at
the end of compression in pre-humidified air (100% R.H.)
BLES S.T.eq S.T.min ɛ Experiment
Batch (mJ/m2) (mJ/m2) (mJ/m2) Month-year
A 23.1 5.5±0.8 101.7±2.9 Feb-05
B 22.6 11.9±0.8 77.6±8.6 May-05
C 26.0 6.5±0.9 103.0±12.7 Jul-05
D 24.1 17.6±0.3 – a Aug-06
D 23.7 15.3±0.2 – a Sep-06
E 23.5 20.4±1.1 – a Jun-06
E 24.3 19.3±0.1 – a Nov-06
E 24.6 14.7±0.4 – a Dec-06
F 22.6 5.5±0.5 109.8±3.5 May-07
Notes:
a These batches showed signs of film collapse before or at 10%, area reduction,
thus no elasticity was calculated.ADSA determines surface tensions by numerically fitting the shape of the drops
to a theoretical profile generated using the Laplace equation of capillarity. Typical
output of ADSA includes surface tension, surface area and volume of the drop.
The dynamic compression/expansion experiments are carried out by peri-
odically injecting/withdrawing liquid from the drop through a motor-controlled
syringe (controller 18705/6, Oriel Instruments, Stratford, CT). The cycle periodicity
and the volume injected/extracted are programmed into the motor controller.
The surface tension procedure encompasses two stages. The first stage involves
forming a drop on the pedestal (within 0.5 s) and tracking the surface tension over
time until the film reaches the equilibrium surface tension value. This is the film
formation stage illustrated in Fig. 1. In this stage, the surface tension of the
suspension decreases from an initial surface tension of nearly 70 mJ/m2 to surface
tension values ranging from 20 to 25 mJ/m2 at equilibrium [1].
Dynamic cycling started once the equilibrium surface tension has been reached.
As shown in Fig. 1, the dynamic cycling consists of four sub-stages: compression,
relaxation, expansion and re-adsorption. One of the main performance parameters
that is obtained from these measurements is the minimum surface tension (STmin)
reached at the end of each compression (See Fig. 1). It is important to note that thisTable 2
Surface active properties of BLES 0.5 mg/ml preparations containing chitosan
Chitosan
concentration
STmin Dilatational elasticity
(ɛ)
Relaxation rate
(γ')
(mg/ml) (mJ/m2) (mJ/m2) (mJ/m2-s)
0 11.9±0.9 86±10 9.6±2.7
0.01 7.2±0.5 101±8 15±3.0
0.05 2.8±0.2 169±5 2.6±1.5
0.0625 3.2±1.2 199±3 0.43±0.08
0.10 3.5±0.5 174±2 0.87±0.23
0.15 8.1±0.6 119±5 11.0±0.91
0.25 17.9±0.4 – a – a
a The film collapsed before reaching A=0.9Ao.
Table 3
Surface active properties of BLES 2.0 mg/ml preparations containing chitosan
Chitosan concentration STmin Dilatational elasticity (ɛ) Relaxation rate
(mg/ml) (mJ/m2) (mJ/m2) (mJ/m2-s)
0 9.7±0.4 84±4 11.5±0.9
0.02 7.9±0.3 94±3 7.2±0.5
0.05 8.7±0.7 121±2 5.1±0.7
0.10 2.7±0.1 168±6 1.2±0.9
0.15 3.4±0.2 167±7 1.9±0.7
0.25 17.4±0.7 – a – a
0.50 18.5±0.5 – a – a
a The film collapsed before reaching A=0.9Ao.
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the rate and extent of compression. Throughout this work we use a compression
periodicity of 3 s/cycle and a compression ratio (fraction of surface area reduction)
of 20% to simulate normal breathing conditions [1,43].
For each of the formulations presented in Tables 1–3, four or more droplets
were tested in CSD experiments, and the results are expressed as the mean±95%
confidence interval (nN4 unless otherwise indicated).
2.2.2. Dilatational elasticity calculation
Dilatational elasticity is a property (ɛ) of the surfactant film that defines the
magnitude of surface tension reduction for a given film compression (surface
area reduction). To calculate this value, the following equation was used [43]:
e ¼ A
Ao
 
dg
d AAo
  : ð1Þ
A is the surface area of the drop at any time, Ao is the surface area of the drop at
the beginning of the compression stage (stage 1 in Fig. 1), and γ is the surface
tension at any time during the compression. To calculate dγ /d(A /Ao) the 3rd
compression cycle of every γ−A /Ao isotherm was isolated (this is when steady
state cycling was reached) and fitted to a 4th order polynomial equation. The slope
(dγ /d(A /Ao)) of the fitted curve evaluated at half compression (A /Ao=0.9) was
calculated to obtain the dilatational elasticity value according to Eq. (1). These
values are listed in Tables 1–3. These calculations were conducted using a digital
differentiator, Savitzky–Golay (SG) filter [44], which takes the first derivative of
the 4th order equation by moving a convolution mask, based on a piecewise least-
squares polynomial fitting, over the experimental data. For some of the for-
mulations presented in Tables 1–3, the surfactant film (adsorbed at the air/water
interface) collapsed even before reaching a compression of A /Ao=0.9, in which
case no elasticity values are reported. The onset of film collapse occurs when
further reduction of surface area of the drop does not yield a reduction in surface
tension. The onset of film collapse and the collapse surface tension are reported in
Tables 1–3.
2.2.3. Surface tension relaxation
To assess the relaxation effects, the rate of surface tension increase (γ'=dγ /dt)
at the beginning of the relaxation stage (Fig. 1, stage 2)was calculated. To calculate
γ', the γ− t data obtained during the relaxation stage of the 3rd cycle was also fitted
to a 4th order polynomial, and the slope (γ'=dγ /dt) in themiddle of this relaxation
stage was obtained using the SG filter introduced above. The calculated values of
γ' are listed in Tables 2 and 3.
2.2.4. Optical microscopy
The aggregates present in the subphase of BLES–chitosan preparations were
observed using an inverted optical microscope (Olympus IMT-2, Lake Success,
NY). Images were taken by a high-resolution digital camera (Sony XCD-SX900,
Toronto, ON, Canada).
2.2.5. Zeta potential measurements
The zeta potential of the surfactant aggregates was determined using a Delsa
440SX Zeta Potential Analyzer (Coulter–Beckman, Miami, FL). The measure-
ments were made at room temperature (25 °C). To prevent the saturation of thelight scattering detectors, each sample was diluted by a factor of 10 in a 0.9%
NaCl solution. Zeta potential measurements of diluted and undiluted 0.5 mg/ml
BLES had the same zeta potential, thus confirming that the dilution procedure
does not change the zeta potential of the aggregates.3. Results and discussion
3.1. Dynamic surface tension of dilute (0.5 mg/ml) BLES
suspensions compressed in pre-humidified air
The surface activity of BLES formulations was tested by
compressing these preparations in an environmental chamber
filled with air pre-saturated with water (100% R.H.). It has been
reported that air pre-saturated with water has a detrimental effect
on the ability of lung surfactant preparations to achieve a low
surface tension upon compression [43,45–47]. Furthermore,
when the same lung surfactant preparations are compressed in dry
air (less than 20% R.H.) the minimum surface tension is
consistently low (i.e. less than 5 mJ/m2) [43,46]. It has been
proposed that the hydration of the lung surfactant film adsorbed at
the air/water interface causes a fluidization effect that promotes
film relaxation, leading to high minimum surface tension upon
compression [43].Various factors, such as the reduced content of
neutral lipids (cholesterol in particular) and surfactant protein SP-
A inBLES preparations have been proposed as the causes of these
film hydration–fluidization phenomena [43,46].
Over the last three years, i.e. the period in which dilute BLES
preparations (0.5 mg/ml) have been evaluated using an envi-
ronmental chamber with pre-humidified air (using the CSD
device), it has been observed that, in the absence of additives, the
minimum surface tension (obtained during dynamic compression
cycles) of these preparations varies widely from batch to batch.
Table 1 summarizes the surface tension at equilibrium, minimum
surface tension, and dilatational elasticity of various batches of
BLES preparations.
In Table 1, the minimum surface tension of dilute (0.5 mg/ml)
BLES preparations ranges from as low as 5.5mJ/m2 to as high as
20.4 mJ/m2. While there are significant variations in the mini-
mum surface tension, the equilibrium surface tension values are
relatively constant for all batches. Furthermore, low elasticity
values, and the onset of film collapse, are observed for those
batches with minimum surface tensions larger than 10 mJ/m2.
These observations highlight that, in the presence of pre-humi-
dified air, the surface activity (expressed in terms of minimum
surface tensions) of dilute BLES preparations tends to be highly
variable.
The reasons behind the high values of minimum surface ten-
sions of dilute BLES preparations in the presence of pre-humi-
dified air are not completely clear. However, it should be reiterated
that BLES is a complex mixture of lipids and proteins. In dilute
BLES preparations, relatively small changes in compositions in
key components such as SP-B (from 1% to 2%) could be res-
ponsible for drastic changes in the surface activity. However, in
clinical applications, high surfactant dosages (up to 100 mg/kg)
are instilled using concentrated solutions of BLES (∼27 mg/ml)
that buffer these changes in surfactant composition, and yield the
desired performance observed in clinical practice [19].
Fig. 2. Surface tension–area–volume (S–A–V) example output for 0.5 mg/ml BLES (part A) and 0.5 mg/ml BLES +0.1 mg/ml chitosan (part B) compressed at 37 °C,
100% R.H., 3 s/cycle periodicity, approximately 20% surface area compression.
Fig. 3. Minimum surface tension (end of compression) as a function of chitosan/
BLES weight ratio for 0.5 and 2.0 mg/ml BLES preparations compressed to a
20% surface area reduction using a cycle periodicity of 3 s/cycle.
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pre-humidified and dry air
Fig. 2 presents a sample output (surface tension–area–
volume) for the dynamic cycling of BLES 0.5 mg/ml and a
lung surfactant formulation containing BLES 0.5 mg/ml and
chitosan 0.1 mg/ml compressed in pre-humidified air (100% R.
H. air). Fig. 2 shows the typical cycle to cycle reproducibility in
terms of surface area, and drop volume is observed from the
third cycle onwards. All the results presented in this work
consider values obtained at the third cycle or shortly afterwards.
Comparing the surface tension and surface area output for
BLES alone (Fig. 2A) and BLES+chitosan (Fig. 2B), it is
evident that the addition of chitosan enabled BLES preparations
to achieve low and stable surface tensions during the compres-
sion stage 2.
In order to determine the effect of chitosan on different
batches of BLES compressed in 100% R.H. air, the minimum
surface tension obtained with different batches of BLES (con-
taining 0.5 mg/ml and 2.0 mg/ml of BLES) is plotted in Fig. 3,
as a function of the chitosan/BLES mass ratio. The addition ofchitosan consistently reduces the minimum surface tension of
BLES batches, independently of the minimum surface tension
of the original batch in the absence of chitosan.
Fig. 4. Dilatational elasticity (ɛ) as a function of chitosan monomer/PG dose
ratio (N+/N−) for 0.5 mg/ml and 2.0 mg/ml BLES formulations. All systems were
compressed in 100% R.H. air.
296 N. Kang et al. / Biochimica et Biophysica Acta 1778 (2008) 291–302Another important feature of Fig. 3 is that the minimum
surface tensions of BLES+chitosan systems compressed in pre-
humidified air are similar to those obtained with a batch of
BLES compressed in dry air (batches A and F) with and without
added chitosan. The data in Fig. 3 suggests that chitosan helps
prevent the fluidization of the surfactant film at the air/water
interface induced by the hydration effects of pre-humidified air
(100% R.H.) [43]. Furthermore, the data presented in Fig. 3
shows that the fluidizing effect of pre-humidified air on dilute
surfactant preparations represents a suitable and simple
framework to investigate the lung surfactant–chitosan interac-
tions. Thus, BLES–chitosan mixtures compressed in 100% R.
H. air are convenient to investigate the interaction between
these two species since no additional species (such as protein
inhibitors) are involved. The studies presented in the following
sections were conducted using batches B and C (Table 1) unless
otherwise specified.
3.3. Effect of chitosan dosage on 0.5 mg/ml BLES suspensions
A close inspection of Fig. 2A reveals that, at the end of the
compression stage (stage 3) the surface tension of the BLES-
alone preparation increases due to relaxation whereas the sur-
face tension of BLES–chitosan preparations (Fig. 2B) remains
constant and low up to the beginning of the expansion stage
(stage 4). The fact that the addition of chitosan suppressed the
surface tension relaxation (i.e. surfactant film relaxation) is
consistent with the stabilizing effect of chitosan against the film
fluidization effect of humidity (preceding section). This
example indicates that additives like chitosan affect various
film properties and that the analysis of the results should not
concentrate on minimum surface tensions only (Fig. 3), but on
the changes of the mechanical properties of the surfactant film
adsorbed at the air/water interface. For this reason, the changes
in film elasticity and relaxation are analyzed as a function of
chitosan dosage in this section. Table 2 summarizes the surface
active properties of mixtures of BLES (0.5 mg/ml) and chitosan,
as a function of chitosan concentration.
According to Table 2, the minimum surface tension decreased
when the chitosan concentration increased from 0.01 mg/ml to
0.05 mg/ml and remained low (less than 5 mJ/m2) within the
range of 0.05 mg/ml to 0.1 mg/ml. The same trend was pre-
viously observed within the range of 0.01 mg/ml to 0.1 mg/ml
chitosan [39]. However, the minimum surface tension increased
for systems containing more than 0.1 mg/ml of chitosan. When
the chitosan concentration was increased to 0.25 mg/ml, the
surfactant film collapsed at a high surface tension of approxi-
mately 18 mJ/m2.
The quality of the film can be assessed using the values of
dilatational elasticity (ɛ) and the rate of surface tension re-
laxation (γ') [43]. The dilatational elasticity (or its reciprocal
value— compressibility) reflects the “stiffness” of the surfactant
film [48], and the rate of surface tension relaxation reflects the
stability of the film [43]. The values of dilatational elasticity (ɛ)
and the rate of surface tension relaxation (γ') in Table 2 suggest
that the optimal chitosan dosage range (for 0.5 mg/ml BLES
systems) lies between 0.05 mg/ml and 0.1 mg/ml chitosan.These chitosan–BLES preparations with high ɛ and low γ′
values are also the systems that yield the lowest minimum
surface tensions during dynamic compression. Further increase
in the chitosan concentration to 0.15mg/ml produces a reduction
of the elasticity, an increase in relaxation rate and minimum
surface tension.
When the concentration of chitosan in the BLES preparation
is 0.25 mg/ml, the lung surfactant film collapses when it reaches
a surface tension of 17.9 mJ/m2. Such film collapse at high
surface tension is typically observed in inhibited lung surfactant
films [1]. This chitosan-induced inhibition resembles the
inhibition produced by cationic peptides reported by Brummer
et al. [49], and is also consistent with the fact that high intra-
venous dosage of chitosan induces lung injury [50]. It is clear,
therefore, that although the addition of chitosan improves the
surface tension of BLES preparation, there is an overdose
threshold where chitosan becomes an inhibitor in itself. This
will be discussed in the following sections.
3.4. Stoichiometric chitosan–BLES (N+/N−) ratio and its
influence on film properties
TheN+/N− “stoichiometric ratio parameter” relates the number
of moles of ionic groups in the polymer to the number of ionic
groups in the phospholipids. This N+/N− parameter was
introduced by Sennato et al. to study the colloidal stability of
liposome–polyelectrolyte systems [51,52]. It has been proposed
that the electrostatic interactions (binding) between the cationic
groups of chitosan (N+) and negatively charged lipids (N−, i.e.
phosphatidylglycerols) in BLES could be responsible for the
observed improvement in minimum surface tension [39]. Simi-
larly, it has been proposed that the interactions between N+ and
N− groups are also responsible for the inhibitory effects of chi-
tosan (chitosan overdosage) [49]. To evaluate this electrostatic
(binding) hypothesis, the properties of the surfactant film formed
at the air/water interface (ɛ, γ') for 0.5 mg/ml BLES (Table 2) and
2.0 mg/ml BLES (Table 3) are interpreted in terms of the
stoichiometric N+/N− dose ratio (Figs. 4 and 5). This “dose ratio”
Fig. 5. Relaxation rate (γ') as a function of chitosan monomer/PG (N+/N−) dose
ratio for 0.5 mg/ml and 2.0 mg/ml BLES formulations. All systems were
compressed in 100% R.H. air.
297N. Kang et al. / Biochimica et Biophysica Acta 1778 (2008) 291–302is calculated based on the total concentration of chitosan and
BLES in the preparations.
The minimum surface tension values of the 2.0 mg/ml BLES
preparations diminish with increasing chitosan concentration
until an optimal chitosan concentration (0.15 mg/ml) is reached.
Based on the minimum surface tension values in Table 3, the
optimal chitosan dosage for 2.0 mg/ml BLES preparations lies
between 0.1 and 0.15 mg/ml chitosan. The maximum values of
dilatational elasticity (ɛ) and minimum relaxation rate (γ') also
occur at 0.15 mg/ml chitosan. However, using the same chitosan
dosage in 0.5 mg/ml BLES does not produce low minimum
surface tensions. The “optimal” chitosan dosage increases as the
surfactant concentration increases, an observation consistent
with the chitosan–BLES binding hypothesis, suggesting the
existence of an optimal stoichiometric ratio.
The electrostatic binding between polyelectrolytes and ionic
phospholipids has been studied in polyelectrolyte-coated
liposomes [51,52]. For systems containing liposomes produced
with ionic phospholipids, abrupt changes in zeta potential and
liposome size occur near N+/N−=1. To explore this concept,
Fig. 4 presents the values of dilatational elasticity (ɛ) plot-
ted against the stoichiometric dose ratio (chitosan monomer
(N+)/phosphatidyl glycerol (N−)) for the formulations presen-
ted in Tables 1 and 2. This N+/N− dose ratio was calculated as
[52]:
Nþ
N
¼ adac  aionCþ  C
þ
aionC  C 
MWC
MWmCþ
ð2Þ
where C+ is the concentration of chitosan in the suspension (in
mg/ml), MWmC+ is the molecular weight of the monomeric unit
in chitosan (glucosamine, MW=179 mg/mmol), C− is the
concentration of the anionic phosphatidylglycerol (assumed to
represent 10% w/w of the BLES concentration — see Ref.
[28]), and MWC
_ is the molecular weight of palmitoyl–oleyl
phosphatidyl glycerol–POPG (MW=767 mg/mmol) which is
assumed to encompass the different PG species [21,53]. The
parameter αdac is the degree of deacetylation of chitosan (80%).
The parameters, αionC+ and αionC− are the degree of ionization
of chitosan and the anionic lipids (PGs), respectively. Thedegree of dissociation of both chitosan and PGs is dependent on
the pH of the solution. Maltseva et al., have shown that in salt
solutions similar to those used in lung surfactants, PG molecules
are fully dissociated (negatively charged) for pH values higher
than 5 [54]. In the case of chitosan, this molecule is charged at
pH values below 6.5 [55]. Within the pH of 5.5 to 6.0 (the pH of
BLES preparations) the chitosan and PG molecules are dis-
sociated and, therefore, αionC+=αionC−∼1. If BLES and chito-
san were mixed at the physiological pH of 6.5–7.0 the PG
species would remain dissociated, but the degree of dissociation
of chitosan (αionC+) could be reduced to 0.7 or less [55]. In those
cases the values of N+/N− should be adjusted using Eq. (2).
Additionally, in the calculation of N+/N− in Eq. (2), the fraction
of cationic proteins SP-B and SP-C that may be bound to the
ionic lipids have not been considered, which may result in an
overestimation (of up to 10%) of the N− groups. Using this
normalization procedure, the dilatational elasticity data is
presented in Fig. 4 for 0.5 mg/ml BLES and 2.0 mg/ml BLES
as a function of the N+/N− dose ratio.
For 0.5 mg/ml BLES formulations, the maximum elasticity
(∼200 mJ/m2) is reached when the N+/N− dose ratio is ap-
proximately 4. Further addition of chitosan produces lower
elasticities and film collapse when N+/N−N9. It is noted that
time-dependent effects were observed for formulations that
produced extremely large aggregates (flakes).
The elasticities of films of 2.0 mg/ml BLES formulations
increase with increasing N+/N− dose ratio up to N+/N−∼2
(0.15mg/ml chitosan) where an elasticity of 175mJ/m2 is reached
(nearly twice that of the BLES-only system). Systems formulated
with N+/N− dose ratios higher than 2.2 experience film collapse
and high minimum surface tensions.
Fig. 5 presents the rate of surface tension relaxation (γ') as a
function of chitosan/PG dose ratio (N+/N−). As the N+/N− ratio
increases, the relaxation rate decreases (more stable films) until
the film reaches a minimum relaxation rate (optimal formulation).
This optimal formulation is achieved when the N+/N− ratio is
close to 2 for 2.0 mg/ml BLES, and close to 4 for the 0.5 mg/ml
BLES formulation.
Both the elasticity and the relaxation rate of BLES formu-
lations are a function of the N+/N− ratio and this supports the
hypothesis that the binding between the positively charged
chitosan and negatively charged lipids (phosphatidyl glycerol)
is responsible for the observed changes in surface activity.
To understand these binding ratios, it is necessary to consider
the potential configurations that the polymer and the ionic lipid
may acquire. If the area per molecule occupied by a glucosamine
group in chitosan is approximately 25 Å2 (see Ref. [56]) and the
area occupied by a fully compressed phosphatidyl glycerol
group is approximately 40 Å2 (see Ref. [57]), it is possible to
calculate the N+/N− ratio that produces a flat “patch” of chitosan
adsorbed on PG molecules. In such a case, N+×25 Å2=
N−×40 Å2≥N+/N−=(40 Å2)/(25 Å2)∼1.6. This theoretical
binding ratio is of the same order of magnitude as the optimal
range of N+/N− ratios obtained for 0.5 mg/ml and 2.0 mg/ml
BLES. However, it should be noted that the ratios calculated
using Eq. (2) do not take into account that there is a fraction of
the chitosan that remains in the solution and is not bound to the
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difference in optimal range observed for 0.5 mg/ml and 2.0 mg/
ml BLES systems.
If this binding hypothesis is correct, then the changes in
surface activity should also correlate with changes of the surface
charge of the surfactant film adsorbed at the air/water interface.
Ideally, the surface charge of the surfactant film adsorbed at the
air/water interface should be measured to track the changes in
film composition/binding. However the use of surface potential
instruments (such as those used in Langmuir troughs) or AFM
imaging using Kelvin probes requires spreading procedures or
film sampling protocols that may affect the chemical environ-
ment of the suspension. Acknowledging that the zeta potential
of the surfactant aggregates in the subphase may not be the same
as the surface potential of the film, the measured zeta potential
of the surfactant aggregates is an indication of the binding
between chitosan and the anionic lipids in BLES [59], and can
be used as an indirect estimate of surface binding.
3.5. Zeta potential BLES–chitosan subphase aggregates
Fig. 6 presents the zeta potential of BLES aggregates as a
function of the chitosan/PG (N+/N−) ratio for 0.5 mg/ml and
2.0 mg/ml BLES preparations. The zeta potential of both formu-
lations in the absence of chitosan is slightly negative (−10 to
−15 mV), and as the N+/N− increased, this zeta potential
increases due to the adsorption of chitosan. The zeta potential of
both preparations (0.5 mg/ml and 2.0 mg/ml BLES) becomes
zero when the N+/N− ratio is close to 1. This is consistent with
the idea that at the point where the positive and negative charges
are balanced, the zeta potential of the aggregates should be zero.
A similar observation was made by Brody et al. [51] in their
study of the interaction between liposomes produced with
cationic lipids and DNA (negatively charged) using zeta poten-
tial measurements.
The interaction between chitosan and PC and PC/PG lipo-
somes has been investigated (using zeta potential measurements)
for the purposes of producing chitosan-encapsulated liposomesFig. 6. Zeta potential of BLES–chitosan suspensions (pH=5.5) containing
0.5 mg/ml BLES and 2.0 mg/ml BLES as a function of chitosan monomer/PG
(N+/N−) molar ratio.(also known as chitosomes) for drug delivery purposes [60–62].
In these studies, the presence of PG was shown to be essential to
the production of negative zeta potential of chitosan-free
liposomes (typically −20 to −25 mV) and its subsequent binding
to chitosan to form a “flat” adsorbed layer that coats the liposome
[61]. Furthermore, it has been proposed that this flat layer of
adsorbed chitosan was irreversibly bound to the liposome since,
after various rinses, it remained on the surface of the liposome and
produced a zeta potential of +25 to +30 mV [61].
In Fig. 6 the transition into a zeta potential plateau region
(saturation) begins at around +20 mV. The data in Fig. 6 also
shows that this plateau transition begins at around a N+/N− ratio
of 2 for 2.0 mg/ml BLES and aN+/N− ratio of about 4 for 0.5 mg/
ml BLES. The maximum elasticity and minimum relaxation
values for both of these formulations occurs when the zeta
potential of the surfactant aggregates range from +10 mV to
+20 mV (area highlighted in Fig. 6). This optimal formulation
“range” is adjacent to the plateau transition region.
The relation between zeta potential and surface active
properties is not specific to chitosan-lung surfactant prepara-
tions. Davies et al. [59] also found that using different mixtures
of lung surfactant and electrolyte solutions, different zeta po-
tential values could be achieved, and that zeta potential values
ranging from −7 to 0 mV produced minimum surface tensions
of 1 mJ/m2 or less. Davies et al. also observed that inhibited
lung surfactant preparations had zeta potential values of either −
30 mV or less, or +30 mV or more.
Despite the similarities between the work of Davies et al. (who
used multivalent cations) and the work presented in this article
(chitosan–cationic polyelectrolyte), there are important differ-
ences that need to be clarified. First, the multivalent cations only
bind to a single lipid or, at best, to neighboring lipids, but a single
cationic polymer chain is capable of binding to numerous anionic
lipids present in the surfactant film. The second difference is that
the optimum performance of chitosan–BLES systems occurs in
the range of +10 mV to +20 mVand not at +0 mV. This could be
explained by the fact that in multiple binding (to form a flat
polymer monolayer), there are a number of unbound positive sites
in the polymer. This multiple binding has been reported by
various researchers who use lipid–polyelectrolyte mixtures to
produce self-assembled monolayers (SAMs) [63–66].
3.6. Aggregation–segregation effects induced by chitosan
The addition of chitosan to BLES preparations also produces
changes in the aggregation state of the lung surfactant. Fig. 7
presents typical micrographs for 0.5 mg/ml and 2.0 mg/ml
BLES without chitosan, with optimal chitosan concentration,
and with an excess chitosan concentration that yields inhibited
surfactant films. According to Fig. 7, the addition of an optimal
dosage of chitosan produces large flocks composed of small
vesicles. Guo et al. [60] observed the same aggregation on PC–
PE liposomes in the presence of chitosan. However, the addition
of excess chitosan (0.25 mg/ml chitosan, see last column of
pictures in Fig. 7) produces a de-aggregation of the flocks.
It is well known in the polymer/colloid literature that the
addition of polyelectrolytes to suspensions of oppositely
Fig. 7. Optical micrographs of surfactant aggregates in suspension. The number in parenthesis corresponds to the minimum surface tension achieved during dynamic
cycling.
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the zeta potential approaches zero, and that addition of excess
polyelectrolyte induces charge reversal and particle de-aggre-
gation [67–70]. The same flocculation/de-aggregation phenom-
enon has also been observed in mixtures of polyelectrolytes with
oppositely charged liposomes [51,52].
In order to correlate the morphology of the surfactant
aggregates with their surface activity, Fig. 8 presents the surface
tension-area compression loops for the systems of Fig. 7. For both
BLES concentrations (0.5 mg/ml and 2.0 mg/ml) presented in
Fig. 7, the addition of an optimal chitosan dosage allows the
compression to be more efficient (minimal film relaxation,
maximal surface tension reduction, and minimal hysteresis). The
addition of a high chitosan dosage (within the plateau region of
Fig. 6) yields BLES preparations that undergo film collapse at a
surface tension of 20–22 mJ/m2.
As deduced from the comparison between Figs. 7 and 8, the
formation of large surfactant aggregates is typically associated
with surfactant films that yield low minimum surface tension
upon dynamic compression [1,4,5,28].
In the case of nonionic polymers, the depletion–attraction
mechanism is the one responsible for the formation of large
surfactant aggregates which is associated with the increase in the
rate of film formation and reversal of surfactant inhibition by serum
proteins [28,36]. The depletion–attractionmechanism requires that
a polymer should not be attracted/adsorbed by the surface of the
particle, and it is even more efficient when the polymer has the
same charge as the surface of the particle (the reason whyhyaluronan is more effective than dextran or polyethylene glycol)
[71]. The data in Fig. 6 clearly shows that chitosan adsorbs on the
surface of the aggregates and opposes the interaction which would
be prescribed by the depletion–attraction mechanism.
The micrographs of Fig. 7 suggest that in optimal BLES–
chitosan formulations chitosan caused the adhesion of lipid
membranes (flocculation of vesicles), but that a chitosan overdose
induced a de-flocculation of such aggregates. In the region
leading to the plateau dosage (noted as optimal formulations in
Fig. 6), chitosan seems to serve as a “bridge” between the negative
groups of different vesicles. The same bridging effect has been
used to explain the interaction between negatively charged DNA
and cationic lipid vesicles [52]. However, with increasing
chitosan dosage, the inter-vesicle bridging appears to be replaced
by the formation of intra-vesicle patches which leads to individual
vesicles decorated with a layer of chitosan. Such individual
vesicles repel each other by virtue of their net positive charge and
the lack of inter-vesicle bridge.
These flocculation and de-flocculation effects may also be
at play between patches of ionic lipids adsorbed at the air/
water interface. The literature on self-assembled monolayers
(SAMS) between polyelectrolytes and monolayers of mixtures
of ionic and zwitterionic lipids supports the idea of a “flat”
adsorption configuration of the polyelectrolyte bridging ionic
lipids of opposite charge [56,63–66,72,73]. Such bridging
among ionic lipid patches at the interface would explain the
superior elasticity and stability of optimal BLES–chitosan
preparations.
Fig. 8. Surface tension (ST)–relative area compression cycles for BLES–chitosan preparations (composition shown in the figure). All systems were compressed in
100% R.H. air.
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the segregation phenomena observed in polyelectrolyte-ionic
lipid monolayers (adsorbed at the air/water interface), where at
high polyelectrolyte concentrations, patches of polyelectrolyte-
bound ionic lipids form separate phases [74]. Furthermore this
lipid demixing (segregation of ionic lipid patches) effect has been
observed in various systems containingmixtures of anionic lipids,
zwitterionic lipids and cationic proteins [75], and has been
associated with an increase of fluidity of the monolayer [75,76].
Such fluidization of the film would explain the poor mechanical
properties (film collapse in particular) of BLES–chitosan systems
formulated within the zeta potential plateau region.
4. Conclusions
When dilute BLES-only preparations are compressed in the
presence of pre-humidified air, the minimum dynamic surface
tension of these systems is relatively high and variable, likely due
to hydration–fluidization effects discussed in previous studies.
This variability can be suppressed with the addition of an optimal
chitosan concentration that depends on the concentration of
BLES. This optimal range is correlated with the binding of
positive charges in chitosan and the anionic lipids in BLES. This
binding to BLES was confirmed by zeta potential measurements
that show that the addition of chitosan to BLES produces an
increase in zeta potential of the subphase aggregates from about
−12 mV to +25 mV. Furthermore, it was shown that the “optimal
dosage range” occurs when the zeta potential of the aggregates isbetween +10 mV and +20 mV. This zeta potential range is the
same for both 0.5 mg/ml and 2.0 mg/ml BLES preparations.
The changes in dynamic surface tension and zeta potential
also correlate with changes in the colloidal stability (flocculation
and de-flocculation) of surfactant subphase aggregates. Within
the optimal chitosan dosage range, the subphase aggregates form
“clusters” of surfactant vesicles that adhered to each other.
These observations highlight the importance of electrostatic
interactions on the properties of lung surfactant systems. Fur-
thermore, the electrostatic binding principles discussed here are
likely relevant to understanding the essential role that cationic
proteins such as SP-B and SP-C play in lung surfactant systems.
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